Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.000604594921402626 -0.000604594921402626 -0.000604594921402626 0.00120918984280525
Stock impact report

First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO 2018

CELGENE (CELG) 
Last celgene earnings: 10/31 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celgene.com
Company Research Source: Business Wire
IMpassion130 reports first positive Phase III study results for a chemotherapy/immunotherapy (ABRAXANE plus atezolizumab) combination in first-line metastatic triple negative breast cancer (TNBC) patients IMpower130 demonstrated significant overall survival (OS) and progression-free survival (PFS) benefit of ABRAXANE/carboplatin plus atezolizumab in advanced non-squamous non-small cell lung cancer (NSCLC) patients SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the first results from the IMpassion130 study evaluating ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with atezolizumab (Tecentriq®) in patients with first-line locally advanced triple negative breast cancer (TNBC) and the IMpower130 study evaluating ABRAXANE/carboplatin in combination with atezolizumab in first-line advanced non-squamous non-small Show less Read more
Impact Snapshot
Event Time:
CELG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CELG alerts
Opt-in for
CELG alerts

from News Quantified
Opt-in for
CELG alerts

from News Quantified